News Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Real-time Estimate Cboe BZX Other stock markets 10:45:27 2024-04-19 am EDT			5-day change	1st Jan Change
32.92 ^USD	-7.46%		-10.48%	+55.95%

03:16pm	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
02:12pm	Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Pre-Bell Friday	09:16am	MT
Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	08:12am	MT
Spyre Therapeutics Announces Grants of Inducement Awards	Apr. 01	PR
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	Mar. 26	MT
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	Mar. 17	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Spyre Therapeutics Announces Grants of Inducement Awards	Mar. 04	AQ
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Spyre Therapeutics Announces Grants of Inducement Awards	Mar. 01	PR
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	Mar. 01	MT
Spyre Therapeutics: Q4 Earnings Snapshot	Feb. 29	AQ
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 29	PR
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference	Feb. 26	PR
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation	Feb. 09	AQ
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors	Feb. 06	AQ
Spyre Therapeutics, Inc. Announces Board Changes	Feb. 05	CI
Spyre Therapeutics Announces Grants of Inducement Awards	Feb. 02	PR
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	Dec. 26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Summary

Filters